Next Score View the next score

    Novartis selling diagnostics unit to Grifols SA

    GENEVA — The pharmaceutical company Novartis said Monday that it is selling part of its diagnostics business to the Spanish company Grifols for $1.68 billion.

    The company, based in Basel, Switzerland, said the deal with Grifols SA, which is based in Barcelona and is the world’s third-largest producer of plasma-derived therapies, requires regulatory approvals but is expected to be completed in the first half of 2014.

    Joseph Jimenez, chief executive of Novartis, said in a statement that the sale of the company’s blood transfusion diagnostics unit ‘‘enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion.’’


    Novartis AG said the unit, which it acquired in 2006 as part of Chiron, an Emeryville, Calif., biotech company, had sales of $565 million in 2012.

    Get Talking Points in your inbox:
    An afternoon recap of the day’s most important business news, delivered weekdays.
    Thank you for signing up! Sign up for more newsletters here

    Novartis has its global research headquarters in Cambridge, Mass.

    Associated Press